Skip to main content

Table 4 Influence of CDKN2 deletion by different TKI treatments

From: Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia

 

Imatinib (n = 26)

Dasatinib (n = 18)

P value

CR after induction

22/26 (84.6 %)

17/18 (94.4 %)

0.634

CMR after induction

2/23 (8.7 %)

4/16 (25.0 %)

0.205

Transplantation

19/26 (73.1 %)

15/18 (83.3 %)

0.489

Relapse

16/26 (61.5 %)

10/18 (55.6 %)

0.691

OS (median time)

16.5 (1.2–38.7)

18.4 (3–41.9)

0.508

DFS (median time)

12.9 (0–37.7)

14.2 (0–41)

0.555

  1. CR complete remission, Allo-HSCT allogeneic hematopoietic stem cell transplantation, DFS disease-free survival, OS overall survival
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us